Mode
Text Size
Log in / Sign up
N/A Completed N=66 Randomized Double-blind Treatment

RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)

Source: ClinicalTrials.gov NCT02246660 ↗
Enrolled (actual)
66
Serious AEs
12.1%
Results posted
Apr 2018
Primary outcomePrimary: 6-Minute Walk Distance, Meters — -12.8; 4.6; -12.3 meters

Summary

The RESTORE trial will determine whether resveratrol supplementation can improve walking performance in older people with lower extremity peripheral arterial disease (PAD). Resveratrol, a polyphenol and natural supplement, specifically targets several impairments associated with walking difficulty and mobility loss in people with PAD.

Outcome Measures

OutcomeResultp-value
PRIMARY
6-Minute Walk Distance, Meters
-12.8; 4.6; -12.3

Eligibility Criteria

Inclusion Criteria

  • Ankle-brachial index (ABI) 1,600 feet )
  • Treated for cancer during the last 2 years (unless prognosis is excellent)
  • Severe hearing impairment or other communication difficulties (e.g. non-English speaking) or legally blind
  • Diagnosis of Parkinson's disease
  • Unable to return to medical center at required visit frequency
  • Otherwise poorly suited to intervention (at the discretion of the PI)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02246660). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search